Seeking AlphaThu, 28 May 2026 19:01:16 GMTApogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended DosingAPGE+5.55%
Investors Business DailyWed, 27 May 2026 14:33:40 GMTWhy Apogee Slipped On Its Dupixent-Rivaling Eczema ResultsAPGE+5.55%
The Motley FoolThu, 26 Mar 2026 15:33:11 GMTApogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for InvestorsAPGE+5.55%
Zacks Investment ResearchTue, 24 Mar 2026 15:31:07 GMTAPGE Stock Up as Skin Disease Drug Shows Sustained 52-Week EfficacyAPGE+5.55%
Seeking AlphaTue, 24 Mar 2026 14:54:39 GMTApogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 MilestoneAPGE+5.55%
Seeking AlphaMon, 23 Mar 2026 21:33:38 GMTApogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis TranscriptAPGE+5.55%
Seeking AlphaMon, 23 Mar 2026 21:12:56 GMTApogee Therapeutics: Two Shots A Year, One Shot At DisruptionAPGE+5.55%
BenzingaMon, 23 Mar 2026 14:04:40 GMTApogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data ReadoutAPGE+5.55%
Investors Business DailyMon, 23 Mar 2026 13:59:03 GMTHow Apogee, Up 14%, Plans To Take On Rival Regeneron's Eczema DrugAPGE+5.55%
